Concall Analysis

Management Guidance

-->Total revenue for this quarter is 1160 crores as compared to 918.6 crores for the same period last year, A growth of around 26%.

-->Net profit for the year was 420.3 crores as compared? to 320.4 crores last year.

-->51 crores was booked as provisions towards patent infringement litigation cases.

-->Company also occurred a one time special incentive to employees of 17 crores.

-->Major growth drivers was due to formulation exports.

-->Amongst domestic products oncology sector gave them good jump, this was partially due to one time order and also due to growth. Revalmid run up will be over by 2026 post that the management is betting on semaglutide, these are the sole FTF in this and they have partnered with Mylan.

-->Also they have a filing called olaparib here also they are the sole FTF and a joint venture with Alembic.

-->They also have Kyprolis and Traceler which are in the mid range segment 30,40 , 100 million types.

-->Management expects that they will see 1000-1200 crores in profits this year comfortably.

-->CTPR is doing well in India and they are expecting to launch that in Brazil also, they are filing it in the US and also other markets as well, but indicates the exports to take of it would take 2-3 years from now.

-->Management is again looking at acquisition and this time they are trying to buy a company in the UK.

-->Management feels that the business is getting more competitive and therefore they wants to go front end in big markets?and for complex generics that are R&D heavy they want to do alliance.

-->On being questioned on what they would do with the remaining money the management says they have spent 250 crores in buyback and 125 crores on dividend.

-->Management is not keen on doing acquisition by borrowing.

-->Management is looking to be in the front end market of 10 countries.

Terminologies:

Formulation exports: It refer to the export of finished medicinal products, like tablets, capsules, syrups, or injectables. These are the drugs that patients typically receive at pharmacies.

NCE: This pipeline refers to the collection of new chemical entities (NCEs) that a pharmaceutical company is developing. NCEs are small molecule drugs that are undergoing clinical trials or have received first approval for a specific use.

Medical Terminologies:

Center for Pharmaceutical Processing Research (CPPR).

Olaparib: It is a medication used to treat specific types of cancer in adults. It falls under the category of targeted therapy, meaning it attacks cancer cells with a specific weakness.

Imbruvica: is a prescription oral medication used to treat several types of blood cancers in adults.

Kyprolis: It is a prescription drug used to treat a specific type of cancer, relapsed or refractory multiple myeloma.

Tracleer: It is a medication used to treat pulmonary arterial hypertension (PAH) in adults.

Lonsurf: It is a prescription medication used to treat specific types of advanced cancers in adults.

Balversa: It is a prescription drug used to treat a specific type of advanced bladder cancer.

?